Tirbanibulin 1% (Klisyri®) ointment is a new, synthetic anti-proliferative agent that works by preventing tubulin polymerization and Src kinase signaling. It is FDA-approved for the topical treatment of AK of the face or scalp. It is a novel, topical first-in-class microtubule inhibitor that represents a significant step forward in the treatment of AK due to its short treatment protocol (once daily application for 5 days), and proven efficacy and safety profile. Klisyri® (tirbanibulin) is supplied in boxes of 5 single-use sachets, and is applied to the treatment area once daily for 5 days.
